# Gene Therapy Under Scrutiny After Nine Tumor Reports

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/neurology/generalneurology/123769) · 2026-11-06 · Medicine
Page: https://themorning.science/story/gene-therapy-under-scrutiny-after-nine-tumor-reports-2cc3b80912aaaf19
Kind: other · Impact: medium

## In brief

- Novartis acknowledged nine reports of tumors in children treated with Zolgensma (onasemnogene abeparvovec) for spinal muscular atrophy.
- The source reports that two of the tumor cases were in the news, but the available text is cut off, so further details are not confirmed here.

## Why it matters

Reports of tumors after a gene therapy approved for a serious childhood disease raise questions about the long-term safety of such treatments, which clinicians and researchers need to monitor.

## Timeline

- 2026-11-06: Novartis acknowledged nine tumor reports in children treated with Zolgensma (reported by MedPage Today)

## Coverage

- [Gene Therapy Under Scrutiny After Nine Tumor Reports](https://www.medpagetoday.com/neurology/generalneurology/123769) — MedPageToday.com - medical news for physicians, 2026-11-06
- [Novartis reveals cancer cases possibly linked to gene therapy Zolgensma](https://www.biopharmadive.com/news/zolgensma-tumor-report-novartis-sma-spinal-muscular-atrophy/873990/) — BioPharma Dive - Latest News, 2026-11-06

Tags: gene therapy, drug safety, spinal muscular atrophy, zolgensma, novartis, tumors

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science